Home> Products> other antidiabetic medications

{ "products": [ { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b8014256f7114dfbd884", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "Trelagliptin 100mg in TRELAQWK 100 is an innovative once-weekly oral medication formulated with Trelagliptin 100mg, specifically designed to support adults in managing type 2 diabetes mellitus (T2DM). As a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, it provides a simplified and effective approach to improving glycemic control when combined with a healthy diet and regular exercise. Its weekly dosing schedule enhances treatment adherence, offering a more sustainable option for long-term diabetes care.\n\nActive Ingredient:\nTrelagliptin 100mg\nA potent, long-acting DPP-4 inhibitor that helps maintain stable blood glucose levels by preserving incretin activity. Incretins are natural hormones that promote insulin release and suppress glucagon, playing a vital role in blood sugar regulation.\n\nCore Benefits:\nConvenient once-weekly dosing enhances patient compliance\n\nEffectively lowers both fasting and postprandial (after-meal) blood sugar\n\nPromotes natural insulin production without contributing to weight gain\n\nCarries a low risk of hypoglycemia, especially when not used with insulin\n\nCan be used alone or in combination with other antidiabetic medications like metformin or sulfonylureas\n\nMechanism of Action:\nTRELAQWK 100 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in regulating blood sugar after meals. By prolonging their activity, Trelagliptin enhances insulin secretion and reduces glucagon levels, resulting in improved glycemic control. Its extended half-life allows for once-a-week administration, setting it apart from daily DPP-4 inhibitors.\n\nDosage & Administration:\nRecommended Dose: One tablet per week, or as advised by your doctor\n\nHow to Take: With or without food, preferably on the same day each week\n\nIf a dose is missed, do not double the next dose; seek guidance from your healthcare provider\n\nPossible Side Effects:\nTRELAQWK 100 is generally safe and well-tolerated. Some individuals may experience:\n\nHeadache\n\nNasopharyngitis (mild cold symptoms)\n\nConstipation\n\nUpper respiratory tract infections\n\nRare allergic reactions such as rashes or skin irritation\n\nSeek immediate medical advice if you experience unusual symptoms such as severe abdominal pain, persistent skin reactions, or signs of pancreatitis.", "price": 3.0, "discountamount": 1.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medical advice", "generally safe", "healthcare provider", "food preferably", "extended halflife", "crucial role", "dpp4 enzyme", "sulfonylureas mechanism", "antidiabetic medications", "low risk", "vital role", "sustainable option", "regular exercise", "healthy diet", "effective approach", "support adults", "trelaqwk 100trelaqwk 100", "hormones play", "natural hormones", "dose seek guidance", "promote insulin release", "degrades incretin hormones", "experience unusual symptoms", "skin irritation seek", "onceaweek administration setting", "improved glycemic control", "regulating blood sugar", "weight gain carries", "suppress glucagon playing", "improving glycemic control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2132, "imageuri": "https://productimages.withfloats.com/actual/6842b80c8a53ae8db15a02ac.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b80c8a53ae8db15a02ac.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:42:25.371Z", "updatedon": "2025-06-11T11:17:09.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2132", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Trelagliptin 100mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin side effects", "Trelagliptin brand name", "Trelagliptin brands in India", "Trelagliptin uses", "Trelagliptin 100mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6825c6cc966e2a18bb4b35a6", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA PIO", "description": "GLIDAPA PIO is a combination oral medication specially formulated to help manage type 2 diabetes mellitus. It combines two powerful antidiabetic agents, dapagliflozin and pioglitazone, to effectively control blood sugar levels. This medication is prescribed to patients when diet and exercise alone do not provide adequate glycemic control. By addressing blood glucose regulation through different mechanisms, GLIDAPA PIO helps reduce the risk of diabetes-related complications and supports overall metabolic health.\n\nKey Ingredients\nDapagliflozin (10mg): A sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by increasing the excretion of glucose through urine.\n\nPioglitazone (15mg): A thiazolidinedione that improves insulin sensitivity by acting on fat, muscle, and liver cells, facilitating better glucose uptake and utilization.\n\nKey Benefits\nHelps maintain stable blood glucose levels in adults with type 2 diabetes.\n\nCombines two complementary mechanisms to enhance blood sugar control.\n\nSupports weight management due to dapagliflozin’s glucose excretion effect.\n\nMay improve insulin sensitivity and reduce insulin resistance.\n\nReduces the risk of diabetes-related complications such as cardiovascular problems when combined with lifestyle changes.\n\nConvenient once-daily tablet formulation.\n\nHow Does It Work?\nDapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting its elimination through urine, which lowers blood glucose. Pioglitazone acts on insulin-responsive tissues, enhancing the body’s sensitivity to insulin. This dual action helps reduce both insulin resistance and excess blood glucose, providing better overall glycemic control. By targeting different pathways, GLIDAPA PIO offers a synergistic effect to manage type 2 diabetes more effectively.\n\nDirections for Use\nTake GLIDAPA PIO exactly as prescribed by your healthcare provider.\n\nUsually taken once daily, with or without food, at the same time each day.\n\nDo not skip doses or stop the medication without consulting your doctor.\n\nMaintain a balanced diet and regular exercise as advised alongside the medication.\n\nInform your doctor about any other medications you are taking to avoid potential interactions.\n\nSide Effects\nSome patients may experience side effects while taking GLIDAPA PIO, including:\n\nUrinary tract infections or increased urination due to dapagliflozin.\n\nWeight gain or swelling caused by pioglitazone.\n\nRisk of low blood sugar (hypoglycemia) when combined with other antidiabetic drugs.\n\nPossible dizziness or fatigue.\n\nRarely, heart failure or bladder cancer risk (associated with pioglitazone).\n\nIf you notice symptoms like excessive thirst, sudden weight gain, swelling, shortness of breath, or any allergic reactions, seek medical advice immediately.", "price": 255.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medication inform", "pioglitazone risk", "regular exercise", "balanced diet", "doctor maintain", "glucose uptake", "notice symptoms", "antidiabetic drugs", "swelling caused", "advised alongside", "skip doses", "healthcare provider", "effectively directions", "synergistic effect", "glycemic control", "cardiovascular problems", "complementary mechanisms", "fat muscle", "diabetesrelated complications", "insulin resistance", "bodys sensitivity", "glidapa pio", "urine pioglitazone 15mg", "taking glidapa pio", "bladder cancer risk", "improve insulin sensitivity", "improves insulin sensitivity", "glidapa pioglidapa pio", "dapagliflozin weight gain", "increased urination due", "urinary tract infections", "experience side effects", "insulinresponsive tissues enhancing", "liver cells facilitating" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2114, "imageuri": "https://productimages.withfloats.com/actual/6825c6ce65488af627fb2e46.png", "tileimageuri": "https://productimages.withfloats.com/tile/6825c6ce65488af627fb2e46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-15T10:49:48.361Z", "updatedon": "2025-05-15T10:50:30.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-pio/2114", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Dapagliflozin 10mg and pioglitazone 15mg tablets", "category": "DIABETIC RANGE", "tags": [ "Dapagliflozin, pioglitazone combination", "Dapagliflozin, pioglitazone combination", "Dapagliflozin Pioglitazone CDSCO" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a359d62a16e824ce228063", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (5mg) , Metformin Hydrochloride (1000mg)", "description": "GLIEMPAFLOZIN MET 5mg/1000mg is a combination medication formulated to manage type 2 diabetes mellitus (T2DM) effectively. It contains Empagliflozin (5mg) and Metformin Hydrochloride (1000mg), two powerful antidiabetic agents that work together to regulate blood sugar levels. This medication helps improve glycemic control, reduce insulin resistance, and lower the risk of diabetes-related complications when combined with a healthy diet and regular exercise.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control – Regulates blood glucose levels by decreasing sugar production and enhancing excretion.\n\nWeight Management – Empagliflozin helps in weight reduction by promoting calorie loss through urinary glucose excretion.\n\nReduced Cardiovascular Risks – Lowers the risk of heart disease in diabetic patients.\n\nImproved Insulin Sensitivity – Enhances the body's response to insulin and reduces insulin resistance.\n\nSupports Kidney Function – Helps prevent diabetes-related kidney complications.\n\nLowers the Risk of Hypoglycemia – Unlike some other diabetes medications, it reduces the chances of sudden blood sugar drops.\n\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN MET 5mg/1000mg combines two distinct yet complementary mechanisms of action:\n\nEmpagliflozin (SGLT2 Inhibitor) – Blocks glucose reabsorption in the kidneys, causing excess sugar to be eliminated through urine, thereby lowering blood sugar levels.\n\nMetformin (Biguanide) – Works by decreasing hepatic glucose production, increasing insulin sensitivity, and reducing intestinal glucose absorption. This results in overall better glycemic control.\n\n \nDirections for Use:\n \n\nTake GLIEMPAFLOZIN MET 5mg/1000mg once or twice daily as directed by your healthcare provider.\n\nSwallow the tablet whole with water; do not crush or chew.\n\nIt is best taken with meals to minimize gastrointestinal side effects.\n\nFollow a balanced diet and engage in regular physical activity for optimal diabetes management.\n\nDo not skip doses or stop medication without consulting a doctor.\n\n \nSide Effects:\n \n\nAlthough GLIEMPAFLOZIN MET 5mg/1000mg is well-tolerated, some individuals may experience side effects such as:\n\nFrequent urination (due to glucose excretion)\n\nDehydration and electrolyte imbalances\n\nGastrointestinal issues – Nausea, vomiting, diarrhea, or stomach discomfort\n\nUrinary tract infections (UTIs)\n\nGenital infections (yeast infections)\n\nLactic acidosis (rare but serious) due to metformin accumulation\n\nLow blood pressure (hypotension)", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "skip doses", "balanced diet", "complementary mechanisms", "hypoglycemia unlike", "bodys response", "heart disease", "weight reduction", "healthy diet", "diabetesrelated complications", "empagliflozin 5mg", "stop medication", "diabetes medications", "frequent urination due", "optimal diabetes management", "combination medication formulated", "glucose excretion dehydration", "experience side effects", "doctor side effects", "regular physical activity", "healthcare provider swallow", "gliempaflozin met 5mg1000mg", "glycemic control directions", "promoting calorie loss", "decreasing sugar production", "powerful antidiabetic agents", "metformin hydrochloride 1000mg" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2046, "imageuri": "https://productimages.withfloats.com/actual/67a359edd87a03335028ee95.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a359edd87a03335028ee95.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:30:14.031Z", "updatedon": "2025-03-27T09:44:28.311Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-5mg-metformin-hydrochloride-1000mg-/2046", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET 5mg/ 1000mg ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin/metformin 5 mg/500 mg", "empagliflozin + metformin combination brand name", "empagliflozin + metformin brand name in india", "Empagliflozin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35767912e6c5ba00a1473", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (5mg) ,Metformin Hydrochloride (500mg)", "description": "GLIEMPAFLOZIN MET is an advanced oral medication designed for the effective management of Type 2 Diabetes Mellitus. This combination of Empagliflozin (5mg) and Metformin Hydrochloride (500mg) helps regulate blood sugar levels, improve insulin sensitivity, and reduce the risk of diabetes-related complications. It is commonly prescribed as part of a comprehensive diabetes care plan, including diet and lifestyle modifications.\n\n \nKey Benefits:\n \n\nEffective Blood Sugar Control – Helps maintain stable blood glucose levels.\nReduces Insulin Resistance – Enhances the body's ability to utilize insulin efficiently.\nPromotes Weight Management – Empagliflozin aids in weight loss by eliminating excess glucose.\nImproves Cardiovascular Health – Lowers the risk of heart disease in diabetic patients.\nSupports Kidney Function – Helps reduce the progression of diabetic kidney disease.\nLower Risk of Hypoglycemia – Unlike some other diabetes medications, it has a lower risk of causing dangerously low blood sugar levels.\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN MET combines two powerful antidiabetic agents to provide synergistic effects:\n\nEmpagliflozin (SGLT2 Inhibitor): Blocks glucose reabsorption in the kidneys, allowing excess sugar to be excreted through urine. This helps lower blood glucose levels effectively.\nMetformin (Biguanide): Works by decreasing glucose production in the liver and improving insulin sensitivity, leading to better glucose utilization by body tissues.\nTogether, these mechanisms help in long-term diabetes management, reducing complications and improving overall well-being.\n\n \nDirections for Use:\n \n\nTake one tablet as prescribed by your healthcare provider.\nPreferably consume with meals to minimize stomach discomfort.\nSwallow the tablet whole with water; do not crush or chew.\nMaintain a healthy diet and exercise routine for optimal results.\nRegular blood sugar monitoring is recommended to track progress.\n \nSide Effects:\n \n\nWhile GLIEMPAFLOZIN MET is generally well-tolerated, some individuals may experience:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nIncreased urination\nMild dehydration\nWeakness or dizziness\nSerious Side Effects (Seek Medical Attention):\n\nKetoacidosis: Unusual fatigue, nausea, vomiting, or breathing difficulties.\nUrinary Tract Infections (UTIs): Burning sensation while urinating, fever, or pelvic pain.\nLactic Acidosis (Rare but Severe): Muscle pain, trouble breathing, irregular heartbeat.\nIf any severe reactions occur, consult a doctor immediately.", "price": 115.0, "discountamount": 35.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "lower risk", "healthy diet", "commonly prescribed", "doctor immediately", "urinating fever", "generally welltolerated", "gliempaflozin met", "exercise routine", "chew maintain", "wellbeing directions", "body tissues", "diabetes medications", "hypoglycemia unlike", "heart disease", "weight loss", "bodys ability", "diabetesrelated complications", "empagliflozin 5mg", "effective management", "glucose utilization", "decreasing glucose production", "powerful antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2043, "imageuri": "https://productimages.withfloats.com/actual/67a35783a4575f9364b319c7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35783a4575f9364b319c7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:19:51.149Z", "updatedon": "2025-03-22T10:21:42.769Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-5mg-metformin-hydrochloride-500mg-/2043", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET 5MG/ 500MG ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin + metformin combination brand name", "Empagliflozin and metformin hydrochloride tablets", "empagliflozin + metformin brand name in india", "empagliflozin 12.5 mg+metformin 500 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66ed2340847254d7d1081d9a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin Tablet IP 25 mg", "description": "ST GLIPTIN 25 is a pharmaceutical product containing Sitagliptin, an effective medication used to control blood sugar levels in individuals with Type 2 diabetes mellitus. It belongs to a class of drugs known as DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). This medication is often prescribed in combination with other antidiabetic drugs or diet and exercise plans to help manage blood sugar levels and reduce the risk of complications associated with diabetes, such as heart disease, nerve damage, and kidney problems.\n\n \nKey Ingredients:\n \n\nSitagliptin Tablet IP 25 mg: The active ingredient Sitagliptin works by increasing the levels of incretin hormones, which help regulate insulin production in response to meals. It also lowers the amount of glucose produced by the liver.\n \nKey Benefits:\n \n\nEffective Blood Sugar Control: ST GLIPTIN 25 helps to manage blood sugar levels in adults with Type 2 diabetes, especially when used alongside proper diet and exercise.\nMinimal Risk of Hypoglycemia: Unlike some other diabetes medications, Sitagliptin generally does not cause hypoglycemia (low blood sugar) when used alone.\nPromotes Healthy Insulin Levels: Sitagliptin helps enhance the body’s natural release of insulin after meals, improving overall glucose management.\nSupports Heart Health: Maintaining stable blood sugar levels can reduce the risk of cardiovascular complications, making it an important part of a diabetes management plan.\n \nHow Does It Work?\n \n\nST GLIPTIN 25 (Sitagliptin) works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones. These hormones play a key role in regulating blood glucose levels by stimulating insulin release and decreasing glucose production in the liver. By inhibiting DPP-4, Sitagliptin increases the levels of active incretin hormones, leading to better control over blood sugar levels, especially after meals.\n\n \nDirections for Use:\n \n\nDosage: The recommended dose is typically 25 mg taken once daily, as directed by your healthcare provider. This dosage may be adjusted based on the individual's health condition and response to treatment.\nMethod: ST GLIPTIN 25 can be taken with or without food. Swallow the tablet whole with a glass of water. To achieve the best results, it's important to take the medication at the same time each day.\nConsistency: It's essential to continue taking ST GLIPTIN 25 as prescribed, even if you feel well. Do not stop the medication without consulting your doctor.\n \nSide Effects:\n \n\nWhile ST GLIPTIN 25 is generally well-tolerated, some individuals may experience side effects such as:\n\nNausea or diarrhea\nHeadache\nUpper respiratory tract infections\nSore throat\nJoint pain", "price": 69.0, "discountamount": 20.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "same time", "Joint pain", "ST GLIPTIN", "proper diet", "Sore throat", "Minimal Risk", "DPP-4 enzyme", "Side Effects", "best results", "Heart Health", "Key Benefits", "nerve damage", "heart disease", "exercise plans", "insulin release", "natural release", "Key Ingredients", "kidney problems", "low blood sugar", "health condition", "DPP-4 inhibitors", "active ingredient", "insulin production", "glucose production", "healthcare provider", "effective medication", "blood glucose levels", "Sitagliptin Tablet IP", "pharmaceutical product", "Healthy Insulin Levels", "active incretin hormones", "Type 2 diabetes mellitus", "other antidiabetic drugs", "diabetes management plan", "stable blood sugar levels", "overall glucose management", "other diabetes medications", "cardiovascular complications", "Effective Blood Sugar Control", "dipeptidyl peptidase-4 inhibitors", "Upper respiratory tract infections" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1978, "imageuri": "https://productimages.withfloats.com/actual/66ed23433e1478b5013cfd1c.png", "tileimageuri": "https://productimages.withfloats.com/tile/66ed23433e1478b5013cfd1c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-20T07:24:48.197Z", "updatedon": "2024-09-20T07:28:37.557Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-tablet-ip-25-mg/1978", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN 25 ", "category": "DIABETIC RANGE", "tags": [ "What is gliptin used for?", "", "What is the use of S gliptin tablet?" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }